Subscribe to our Newsletters !!
Few developments in science and technology have be
In laboratories where precision is key, like pharm
The recent rabies death of an 11 year old Canadian
Alembic Pharmaceutica
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
The Drug Controller General of India (DCGI) has affirmed the utilization of hostile to viral medication Favipiravir for COVID-19 patients for confined use. The medication can be utilized distinctly if there should be an occurrence of a crisis and family assent of the patient is obligatory.
The term of the course is 14 days.
Glenmark Pharma is at present directing preliminaries for Favipiravir for use on coronavirus licenses. While the preliminaries are as yet in progress, the DCGI affirmed the medication in the wake of seeing empowering results.
The medication controller said observation for the initial 1,000 patients will be required in the wake of regulating Favipiravir to them.
While the medication is commonly utilized for flu around the world, Russia, China
